Two efforts to transform injectables into robotic pills — a colossal market designed to enhance treatment compliance, diminish the need for physician-led therapeutic administration and placate needle-phobic patients — got off the ground last year. Now, one of these initiatives, led by an inventor who played an influential role in pioneering the first FDA-approved automatic implantable cardioverter defibrillator (ICD) has taken another key step in its quest with a successful early-stage efficacy and safety study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,